The ONTARGET/TRANSCEND Trial Programme: Baseline data

Acta Diabetologica

Volumn 42, Issue SUPPL. 1, 2005, Pages

  Sleight, P ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Angiotensin II receptor blocker; Angiotensin converting enzyme inhibitor; Cardiovascular disease; Prevention; Ramipril; Telmisartan

Indexed keywords

ACETYLSALICYLIC ACID; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTICOAGULANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; CHLORTALIDONE; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FIBRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LISINOPRIL; LOSARTAN; NITRIC ACID DERIVATIVE; ORAL ANTIDIABETIC AGENT; PERINDOPRIL; PLACEBO; RAMIPRIL; TELMISARTAN; VERAPAMIL; BENZIMIDAZOLE DERIVATIVE; BENZOIC ACID DERIVATIVE;

ARTICLE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; DIABETES MELLITUS; HEALTH CARE COST; HEART FAILURE; HEART INFARCTION; HEART PROTECTION; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; KIDNEY DYSFUNCTION; MORBIDITY; MORTALITY; POPULATION RISK; PRIORITY JOURNAL; RISK FACTOR; RISK REDUCTION; STROKE; TREATMENT OUTCOME; AGED; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; MALE; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL;

AGED; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BENZIMIDAZOLES; BENZOATES; CARDIOVASCULAR DISEASES; FEMALE; HUMANS; HYPERTENSION; MALE; PROSPECTIVE STUDIES; RAMIPRIL;

EID: 18744380400     PISSN: 09405429     EISSN: 14325233     Source Type: Journal    
DOI: 10.1007/s00592-005-0181-3     Document Type: Article

References (23)

1. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R (2002) Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 360:1903-1913
2. Kannel WB (1985) Lipids, diabetes, and coronary heart disease: insights from the Framingham Study. Am Heart J 110:1100-1107
3. Kannel WB, Stampfer MJ, Castelli WP, Verter J (1984) The prognostic significance of proteinuria: the Framingham study. Am Heart J 108:1347-1352
4. Levy D, Kannel WB (1988) Cardiovascular risks: new insights from Framingham. Am Heart J 116:266-272
5. Levy D, Wilson PW, Anderson KM, Castelli WP (1990) Stratifying the patient at risk from coronary disease: new insights from the Framingham Heart Study. Am Heart J 119:712-717
6. Mann JF, Gerstein HC, Dulau-Florea I, Lonn E (2003) Cardiovascular risk in patients with mild renal insufficiency. Kidney Int 64[Suppl 83]:S192-S196
7. Stamler J, Vaccaro O, Neaton JD, Wentworth D (1993) Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 16:434-444
8. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, McQueen M, Budaj A, Pais P, Varigos J, Lisheng L, INTERHEART Study Investigators (2004) Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 364:937-952
9. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G, The Heart Outcomes Prevention Evaluation Study Investigators (2000) Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 342:145-153
10. Sleight P, Yusuf S, Pogue J, Tsuyuki R, Diaz R, Probstfield J (2001) Blood-pressure reduction and cardiovascular risk in HOPE study. Lancet 358:2130-2131
11. Collins R, Armitage J, Parish S, Sleight R Peto R (2004) Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions. Lancet 363:757-767
12. Fox KM, EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators (2003) Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 362:782-788
13. Wing LM, Reid CM, Ryan P, Berlin LJ, Brown MA, Jennings GL, Johnston CI, McNeil JJ, Macdonald GJ, Marley JE, Morgan TO, West MJ (2003) A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med 348:583-592
14. The ALLHAT Officers and Coordinators (2002) Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. JAMA 288:2981-2997
15. Grimm RH Jr, Margolis KL, Papademetriou V, Cushman WC, Ford CE, Bettencourt J, Alderman MH, Basile JN, Black HR, DeQuattro V, Eckfeldt J, Hawkins CM, Perry HM Jr, Proschan M (2001) Baseline characteristics of participants in the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Hypertension 37:19-27
16. Carson P, Ziesche S, Johnson G, Cohn JN (1999) Racial differences in response to therapy for heart failure: analysis of the vasodilator-heart failure trials. Vasodilator-Heart Failure Trial Study Group. J Card Fail 5:178-187
17. Weir MR, Gray JM, Paster R, Saunders E (1995) Differing mechanisms of action of angiotensin-converting enzyme inhibition in black and white hypertensive patients. The Trandolapril Multicenter Study Group. Hypertension 26:124-130
18. Ertl G, Hu K (2001) Anti-ischemic potential of drugs related to the renin-angiotensin system. J Cardiovasc Pharmacol 37[Suppl 1]:S11-S20
19. Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Rristiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H, for the LIFE study group (2002) Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 359:995-1003
20. McMurray JJ, Ostergren J, Swedberg K, Granger CB, Held P, Michelson EL, Olofsson B, Yusuf S, Pfeffer MA (2003) Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 362:767-771
21. Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, Olofsson B, Ostergren J (2003) Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved trial. Lancet 362:777-781
22. Gavras HP (2001) Issues in hypertension: drug tolerability and special populations. Am J Hypertens 14[7 Pt 2]:231S-236S
23. Teo K, Yusuf S, Sleight P, Anderson C, Mookadam F, Ramos B, Hilbrich L, Pogue J, Schumacher H, ONTARGET/TRANSCEND Investigators (2004) Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials. Am Heart J 148:52-61